Decarbonizing the Production of Low Endotoxin Water
Ultrapure water is perhaps the most prevalent ingredient in biologics manufacturing. Compared to small-molecule drugs, therapeutic proteins produced by cell culture or microbial fermentation can use as much as 10 to 100 times more water. As more and more novel biologics scale up from the lab into commercial production, there is greater pressure to generate more water with higher energy demands and an even higher environmental burden. The challenge for facilities is to satisfy this rapid growth without compromising carbon neutrality goals.